Proceedings (Baylor University. Medical Center) · 2026
Young-onset signet ring cell colorectal adenocarcinoma: demographics, clinicopathological profile, and survival analysis.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Khan Marjan, Sengupta Sohawm, Bansal Puneet, Lee Kue Tylor, Ahmed Asim, Iqbal Asif, Wali Agha, Jain Hritvik, Khan Israr, Rasool Basil, Balkhi Mumtaz Yaseen, Zarak Muhammad Samsoor, Khan Mahrukh, Cheedella Naga K Sucharita, Nadeem Muhammad Ahmad, Nemeth Cecille, Sohail Amir Humza, Ullah Asad
Аннотация
BACKGROUND: Signet ring cell carcinoma (SRCC), a rare subtype of colorectal adenocarcinoma, is associated with high rates of metastasis at presentation and poor prognosis. This study highlights demographic patterns, survival outcomes, and prognostic factors in young-onset SRCC.
METHODS: A retrospective analysis of SRCC patients <50 years was conducted using the Surveillance, Epidemiology, and End Results database (2000-2020).
RESULTS: There was a high prevalence of SRCC in young patients, with a median age at diagnosis of 41.0 years. A significant proportion of cases were in individuals ages 36 to 50. The rectum was the most common primary site (29.1%), and the liver was the most frequent site of metastasis at presentation (8.9% of patients with known metastases). Surgery combined with adjuvant chemotherapy yielded the highest 5-year survival (24.4%; 95% confidence interval [CI], 22.1-26.7), compared with chemotherapy alone (2.6%; 95% CI, 1.2-4.0). Multivariate analysis identified advanced stage, nodal positivity, distant metastases (hazard ratio 7.02; 95% CI, 4.66-10.56), and larger tumor size as significant adverse prognostic factors (all P < 0.001).
CONCLUSIONS: Colorectal SRCC is an aggressive malignancy that disproportionately affects patients <50 years and frequently presents at advanced stages, underscoring the importance of earlier screening.
METHODS: A retrospective analysis of SRCC patients <50 years was conducted using the Surveillance, Epidemiology, and End Results database (2000-2020).
RESULTS: There was a high prevalence of SRCC in young patients, with a median age at diagnosis of 41.0 years. A significant proportion of cases were in individuals ages 36 to 50. The rectum was the most common primary site (29.1%), and the liver was the most frequent site of metastasis at presentation (8.9% of patients with known metastases). Surgery combined with adjuvant chemotherapy yielded the highest 5-year survival (24.4%; 95% confidence interval [CI], 22.1-26.7), compared with chemotherapy alone (2.6%; 95% CI, 1.2-4.0). Multivariate analysis identified advanced stage, nodal positivity, distant metastases (hazard ratio 7.02; 95% CI, 4.66-10.56), and larger tumor size as significant adverse prognostic factors (all P < 0.001).
CONCLUSIONS: Colorectal SRCC is an aggressive malignancy that disproportionately affects patients <50 years and frequently presents at advanced stages, underscoring the importance of earlier screening.